- On 27 June 2026, Diversified Healthcare Trust (NasdaqGS:DHC) was removed from several Russell indices, including the Russell 3000E, Russell 3000E Value, Russell Microcap, and Russell Microcap Value benchmarks.
- This broad index exclusion can alter who holds the stock and how it trades, as index-tracking funds and some institutions adjust their portfolios.
- Next, we examine how DHC’s removal from multiple Russell indices interacts with its existing investment narrative and risk profile.
This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
Diversified Healthcare Trust Investment Narrative Recap
To own Diversified Healthcare Trust, you need to believe its senior housing and healthcare real estate can eventually translate improving operations into a more sustainable financial footing, despite current losses. The Russell index removals may affect trading liquidity and short term volatility, but they do not directly change the core near term catalyst, which remains execution on occupancy, margins and deleveraging, or the biggest risk, which is the company’s elevated leverage and refinancing exposure.
In this context, the most relevant recent update is the Q1 2026 earnings release, which showed revenue of US$366.47 million and a wider net loss of US$43.28 million. Those figures highlight how important it is for DHC to manage interest costs and asset sales prudently while improving property level performance, because any pressure on funding access or borrowing costs after index removal could compound already fragile earnings.
Yet even if index changes seem technical, investors should be aware that refinancing risk and high leverage could quickly become more than just a background concern...
Read the full narrative on Diversified Healthcare Trust (it's free!)
Diversified Healthcare Trust's narrative projects $1.7 billion revenue and $319.2 million earnings by 2029. This requires 4.5% yearly revenue growth and roughly a $639.4 million earnings increase from -$320.2 million today.
Uncover how Diversified Healthcare Trust's forecasts yield a $8.75 fair value, a 8% downside to its current price.
Exploring Other Perspectives
While the baseline view focuses on balance sheet strain, the most optimistic analysts were assuming revenue could reach about US$1.8 billion and earnings of roughly US$326 million, so DHC’s index removal could prompt you to reassess whether that much stronger scenario still feels realistic.
Explore 2 other fair value estimates on Diversified Healthcare Trust - why the stock might be worth 8% less than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Diversified Healthcare Trust research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Diversified Healthcare Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Diversified Healthcare Trust's overall financial health at a glance.
Want Some Alternatives?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com